UAE Grants Emergency Use Authorization for COVID-19 Vaccine from Chinese Pharmaceutical Company

[Asia Economy Reporter Jeon Jinyoung] The United Arab Emirates (UAE) approved the emergency use of a novel coronavirus (COVID-19) vaccine developed by the Chinese pharmaceutical company Sinopharm on the 14th (local time), according to major foreign media. It is reported that full-scale use will begin after a six-week clinical trial involving human subjects in the Gulf Arab countries is completed.

The UAE health authorities stated, "The vaccine will be used for medical personnel who are at high risk of COVID-19 infection due to their frontline work with patients."

They also explained that although there were some side effects reported in the clinical trials, none were fatal. Approximately 31,000 volunteers participated in the Sinopharm vaccine clinical trials conducted in the UAE since July this year. The Abu Dhabi government also revealed that all volunteers in the first and second phases of the Sinopharm clinical trials developed antibodies within about a month.

The UAE government is recently concerned about the resurgence of COVID-19. As of the 14th, the UAE's cumulative confirmed COVID-19 cases reached 80,266, with 777 new daily cases recorded on that day.

Earlier, Russia officially approved the use of a COVID-19 vaccine on the 11th of last month after two months of clinical trials.

This content was produced with the assistance of AI translation services.